Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2025-06-26 Regulatory Filings
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release from GenSight Biologics announcing a major operational milestone: the successful transfer of the upstream manufacturing process for their drug candidate LUMEVOQ® to their new manufacturing partner, Catalent. It details progress related to clinical supply, compassionate access programs, and future regulatory submissions. This type of announcement, focusing on operational updates, strategic partnerships, and progress toward clinical/regulatory goals, is characteristic of a general corporate update or news release. It is not a formal regulatory filing like a 10-K, a specific financial report like an IR or ER, or a proxy statement. Since it is a detailed announcement of business progress and partnership execution, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement, or potentially a Capital/Financing Update (CAP) if the partnership involved significant financial terms, but the focus here is operational progress. Given the options, RNS serves as the best general category for significant, non-standardized corporate news releases that aren't explicitly covered elsewhere (like ER, 10-K, or DIV). It is not short enough to be an RPA.
2025-06-26 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and announces a specific business development: reaching an agreement with the French agency ANSM regarding an Early Access Program (AAC) for LUMEVOQ®. It details timelines for clinical studies and regulatory milestones, and discusses the company's financing strategy to support these events. This type of announcement, focusing on operational updates, regulatory progress, and future catalysts, is characteristic of a general corporate update or press release. Since it is not a full financial report (10-K, IR), a specific financial disclosure (ER, MRQ), or a formal regulatory filing detailing insider trades (DIRS) or shareholder votes (DVA), the most appropriate classification is the general regulatory announcement/press release category, which aligns best with 'Regulatory Filings' (RNS) as a broad category for non-standard, material corporate news, or potentially 'Capital/Financing Update' (CAP) due to the significant discussion on financing strategy, but the primary focus is the regulatory agreement. Given the options, RNS serves as the best fit for a material press release that doesn't fit a more specific financial or governance code. The document length (8014 chars) is substantial, indicating it is the primary content, not just an announcement of another report (ruling out RPA).
2025-06-12 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Communiqué de presse") dated June 12, 2025, detailing an agreement with the French regulatory authority (ANSM) regarding a Compassionate Access Program (AAC) for LUMEVOQ®. It discusses regulatory timelines (dose-ranging study submission in Q3 2025, AAC opening by Q4 2025), future clinical trials (Phase III in 2026), and explicitly mentions the need for financing to cover operations until these milestones are met. It also references the 2024 Universal Registration Document filed with the AMF. This content is characteristic of an announcement providing operational and regulatory updates, often related to financing needs and strategic progress, but it is not a full financial report (10-K or IR), a formal earnings release (ER), or a transcript (CT). Since it discusses financing strategy and operational progress following regulatory discussions, it aligns best with a general corporate update. Given the options, it is a significant corporate announcement. It is not a specific financing document (CAP) as it's primarily an update on regulatory access, nor is it a formal Earnings Release (ER) which focuses on results. It is a general corporate update that doesn't fit the highly specific categories like DIRS, DIV, or NAV. Therefore, the most appropriate general category for a significant, non-standard regulatory/operational update is Regulatory Filings (RNS), which serves as a broad category for important announcements not covered elsewhere, or potentially Capital/Financing Update (CAP) due to the heavy emphasis on funding needs, but the core news is the ANSM agreement. Given the nature of the announcement (regulatory progress and associated funding strategy), RNS is the safest fallback for a press release of this nature that isn't a core financial report or a specific transaction notice. However, since it heavily discusses the need for financing to support regulatory steps, 'CAP' (Capital/Financing Update) is also a strong candidate. I will lean towards RNS as it is a general press release about regulatory progress, which is often filed under general regulatory announcements when a more specific code isn't perfect.
2025-06-12 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document explicitly announces the results of the 'Combined General Meeting of shareholders' held on May 13, 2025. It details which resolutions were adopted or rejected and mentions that the voting results will be made available. This content directly relates to the official outcomes of a shareholder meeting. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it mentions the AGM, the focus is on the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2025-05-13 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press release titled "GenSight Biologics annonce l'approbation de l'ensemble des résolutions soutenues par le Conseil d'Administration lors de son assemblée générale mixte du 13 mai 2025". It explicitly details the results of the Annual General Meeting (Assemblée Générale Mixte), stating which resolutions were adopted and the quorum achieved. This directly relates to the outcomes of a shareholder vote following an AGM. The most specific category for official results from shareholder votes at any general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions the AGM, the core content is the voting outcome, not the AGM presentation itself (AGM-R) or proxy materials (PSI).
2025-05-13 French
Inside Information / Other news releases
AGM Information Classification · 98% confidence The document explicitly announces the date, time, and location for the 'Annual General Meeting' (AGM) of GenSight Biologics. It details the procedures for obtaining preparatory documents and references the legal requirements for convening such a meeting under the French Commercial Code. Since the text is an announcement about the AGM itself, and not the voting results (DVA) or the detailed proxy materials (PSI), the most appropriate classification is AGM Information (AGM-R). The document length is relatively short (3389 chars), but its primary purpose is to serve as the official notice/information regarding the meeting, fitting the AGM-R definition better than a general RPA or RNS.
2025-04-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.